Relugolix meaningfully reduces endometriosis pain
The Phase III trials saw 75 percent of women in the relugolix combination therapy group achieve a reduction in dysmenorrhea (menstrual pain), compared with 30 percent or less of women in the placebo groups.
Results of the Myovant Sciences and Pfizer Phase III SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40mg plus estradiol 1.0mg and norethindrone acetate 0.5mg) in over 1,200 women with moderate to severe pain associated with endometriosis, have been published in The Lancet.
As previously reported, both studies achieved their co-primary endpoints by demonstrating clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain in women with endometriosis. SPIRIT 1 and 2 each met their co-primary endpoints with 75 percent of women in the relugolix combination therapy group in both studies achieving a clinically meaningful reduction in dysmenorrhea, compared with 27 percent and 30 percent of women in the placebo groups at week 24, respectively (both p < 0.0001).
For non-menstrual pelvic pain, relugolix combination therapy achieved a clinically meaningful reduction in 59 percent and 66 percent of women, compared with 40 percent and 43 percent of women in the placebo groups (p < 0.0001). In the studies, seven and six key secondary endpoints, respectively, comparing relugolix combination therapy with placebo at week 24 achieved statistical significance, including reductions in dyspareunia and opioid use. In addition, more women treated with relugolix combination therapy groups were opioid free at week 24 compared with placebo (86 percent and 82 percent versus 76 percent and 66 percent, respectively). In both studies, relugolix combination therapy was associated with a generally well-tolerated safety profile, including bone mineral density loss of less than one percent over 24 weeks.
“Approximately 7.5 million premenopausal women in the United States have endometriosis and 75-80 percent of them are symptomatic,” commented Dr Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences, Inc. “The published data published underscore the value relugolix combination therapy may provide as a potential new treatment option for women with endometriosis-associated pain.”
The secondary endpoints include changes in mean dysmenorrhea, non-menstrual pelvic pain, overall pelvic pain, impact of pain on daily activities as measured by the Endometriosis Health Profile-30 (EHP-30) pain domain, the proportion of women not using opioids, the proportion of women not using analgesics, and change in mean dyspareunia (painful intercourse). While the seventh endpoint for the SPIRIT 2 study – reduction in analgesic use (based on pill count) – did not achieve statistical significance, possibly due to the low number of average pills per day and variability in day-to-day pill consumption, a post-hoc analysis of SPIRIT 2 showed that the percentage of patients who were analgesic-free at the end of treatment was greater among women in the combination therapy group than the placebo group.
The most frequently reported adverse events in both relugolix combination treatment and placebo groups were headache, nasopharyngitis and hot flushes.